Introduction
Effect of platelet-rich plasma on cells
Chondrocytes
Proliferation
Cell type | Intervention | Outcome | Reference |
---|---|---|---|
Porcine chondrocytes | 10% PRP releasate after thrombin and CaCl2 activation | Increased cell proliferation, proteoglycan and Col II synthesis | [29] |
Human osteoarthritic chondrocytes | Bovine fibrin + L-PRF releasate on two-dimensional surface and in three-dimensional scaffold | Increased cell proliferation and Col II and aggrecan mRNA expression and GAG and proteoglycan accumulation | [30] |
Human osteoarthritic chondrocytes | 5% PRP releasate obtained by two cycles of freezing and thawing | Increased cell proliferation, proteoglycan synthesis, Sox-9 and aggrecan mRNA expression and proteins associated with chondrocyte differentiation | [31] |
Bovine chondrocytes | Platelet supernatant | Stimulated proliferation, but failed to induce deposition of typical cartilaginous ECM | [32] |
Human chondrocytes | 1% or 10% platelet supernatant (leukocyte-filtered) | Accelerated cell expansion, but reduced Col II mRNA expression and induced chondrocytes towards a fibroblast-like phenotype | [33] |
Sheep chondrocytes | Double-spun PRP activated by CaCl2 | Stimulated cell proliferation, but reduced Col II mRNA expression | [34] |
Rabbit chondrocytes | Hydrogel + chondrocytes with double-spun PRP | Enhanced chondrogenic differentiation and maturation with up-regulation of CB1 and CB2 | |
Human osteoarthritis chondrocytes | Gelatin microcarriers + biological glues (whole blood, PPP, PRP, or commercial fibrin glue) | No difference in ECM production between any two of these groups | [38] |
Human osteoarthritic chondrocytes | 10% L-PRP releasate after CaCl2 activation | Decreased IL-1β-induced inflammatory effects and inhibited NF-κB activation | [39] |
Immortalized human chondrocytes | PRP releasate activated by CaCl2 | Decreased COX-2 expression and inhibited NF-κB activation via HGF and TNF-α | [40] |
Differentiation
Anti-inflammation
Adult mesenchymal stem cells
Bone marrow-derived mesenchymal stem cells
Cell type | Intervention | Outcome | Reference |
---|---|---|---|
Sheep BMSCs | Double-spun PRP activated by CaCl2 | Increased cell proliferation and Col II mRNA expression | [34] |
Human BMSCs | 50% platelet lysate after two cycles of freezing and thawing | Promoted proliferation and triggered chondrogenic differentiation | [55] |
Human BMSCs | 10% inactivated PRP (leukocyte concentration unreported) | Enhanced cell proliferation and Sox9, aggrecan and RUNX2 mRNA expression | [56] |
Rabbit BMSCs, ADSCs | 10% double-spun inactivated PRP | Increased cell proliferation and expression of Sox9, aggrecan, Col II and Col I mRNA and proteins | [21] |
Mouse MDSCs | Double-spun PRP | Promoted cell proliferation, adhesion and migration of MDSCs, and increased number of cells producing Col II and cell apoptosis | [58] |
Human subchondral progenitor cells | 5% P-PRP after freezing and thawing | Increased cell migration and cartilaginous matrix formation, but did not affect osteogenic and adipogenic differentiation | [60] |
Adipose- and muscle-derived stem cells and human subchondral bone-derived progenitor cells
Scaffolding activity
Synoviocytes
Effect of platelet-rich plasma on cartilage repair in animal models in vivo
Cartilage defect models
Animal model | Defect size | Intervention | Outcome | Reference |
---|---|---|---|---|
Rabbit osteochondral defect in trochlea | 4 mm diameter, 3 mm depth | Untreated; double-spun PRP activated by CaCl2; PRP gel + ADSCs; PRP gel + BMSCs | PRP group yielded better macroscopic and histological results than untreated, but worse than PRP with cells | [21] |
Rabbit osteochondral defect in trochlea | 5 mm diameter, 4 mm depth | Untreated; double-spun PRP activated by thrombin and CaCl2 + PLGA; PLGA | Macroscopic examination, micro-CT, and histology of newly formed osteochondral tissue differed significantly between PRP-treated and untreated groups | [75] |
Rabbit osteochondral defect in trochlea | 4 mm diameter, 3 mm depth | Untreated; collagen scaffold alone or with doule-spun inactivated PRP | PRP-collagen group had highest histological scores and most GAG content; mechanical property was only better than that in the untreated group. | [76] |
Sheep osteochondral defect in femoral condyle | 7 mm diameter, 9 mm depth | Untreated; collagen-hydroxyapatite scaffold alone or with L-PRP activated by CaCl2 | Good integration of the chondral surface in both treatment groups; better osteochondral reconstruction in the group treated with scaffold alone than with PRP | [77] |
Goat osteochondral defect in trochlea | 6 mm diameter, 0.8 mm depth | Engineered cartilage implants with periosteal flap or L-PRP or human fibrin | PRP and human fibrin glue interfered with retention of the implants and integration with adjacent cartilage | [78] |
Sheep chondral defect in femoral condyle | 8 mm diameter, cartilage only | Microfracture alone or with five weekly P-PRP intra-articular injections | PRP enhanced the macroscopic, histological and biomechanical characteristics at 3 months, 6 months and 12 months, but did not produce hyaline cartilage | [79] |
Sheep chondral defect in femoral condyle | 8 mm diameter, cartilage only | Microfracture alone, with single P-PRP injection or with P-PRP and fibrin gel filling up the defects | PRP with fibrin gel yielded the best histological results and biomechanical results, close to those of the normal cartilage, but still did not produce hyaline cartilage | [80] |
Arthritis models
Model or disease | Intervention | Outcome | Reference |
---|---|---|---|
Traumatic OA model in rabbits induced by ACLT | Injections of PBS, PBS-microspheres, PRPr after thrombin and CaCl2 activation or PRPr-microspheres | OA occurred in 25% of the PBS group, 33% of the PBS-microsphere group, and 25% of the PRP group, but no joints in the PRP-microsphere group showed OA changes at 10 weeks | [65] |
Non-traumatic OA model in rabbits induced by collagenase | P-PRP or saline intra-articular injection at 4 weeks after collagenase infiltration | Significantly lower macroscopic and microscopic scores in the PRP-treated group than in the saline-treated group at 8 weeks | [81] |
BSA-induced rheumatoid arthritis model in pigs | Double-spun, inactivated PRP intra-articular injections or saline at 2 weeks and 4 weeks after BSA injection | PRP suppressed the decrease of proteoglycan and Col II content in cartilage and the increase of inflammatory cytokines in synovium and cartilage induced by BSA at 6 weeks | [82] |
Primary OA or osteochondrosis in horses | Three P-PRP intra-articular injections at 2 week intervals | PRP diminished synovial effusion and lameness in the affected joints significantly during 1 year follow-up | [83] |
Equine arthritis
Effect of platelet-rich plasma on human cartilage injury
Focal cartilage lesions
Patient number (age/range) | Defect position | Lesion size or grade | Innervation | Follow-up (months) | Outcome | Reference |
---|---|---|---|---|---|---|
1 (12 years) | Medial femoral condyle | >2 cm2 full-thickness avulsion | Reattachment of loose body and P-PRP injection | 9 | Complete reattachment and perfect continuity on MRI at 18 weeks; return to soccer training at 18 weeks and fully involved in competition at 9 months | [86] |
5 (21–37 years) | Femoral condyle | 3-12 cm2, full-thickness | Cultured autologous BMSC + platelet-rich fibrin glue | 14.2 | All patients symptoms improved; ICRS nearly normal in 2 patients; MRI showed complete defect fill in 3 patients | [87] |
5 (24–45 years) | Patellar cartilage | 1-3 cm2; ICRS grade III or IV | Col I/III scaffold with L-PRP gel | 24 | VAS pain scores were reduced and function improved, but intralesional osteophytes in 3 patients and irregular surface were found in all | [88] |
20 (15–50 years) | Knee osteochondral lesions | ICRS grade III or IV | HA membrane + BM concentrate + P-PRP gel | 29 | IKDC improved from 32.9 to 90.4; KOOS from 47.1 to 93.3; Col II positive and Col I negative staining in entire biopsies in 2 patients | [89] |
48 (15–50 years) | Talar osteochondral lesions | 1.6-2.6 cm2; 3–5 mm deep | Collagen or HA membrane + BM concentrate + P-PRP gel | 29 | AOFAS improved from 64.4 to 91.4; 94% return to low-impact sports at 4.4 months; varying regeneration on MRI and histological exam | [90] |
52 (25–65 years) | Femoral and tibial condyle | 1.5-5 cm2; Outerbridge III or IV | PGA-HA scaffold immersed in P-PRP and BM stimulation | 12 | All KOOS subscores improved; nearly normal appearance in 10 during arthroscopy; hyaline-like cartilage formation in 5 biopsies | [91] |
Degenerative joint diseases
Level IV case series
Level of evidencea | Patient number (age/range) | Intervention | Follow-up | Outcome | Adverse effects | Reference |
---|---|---|---|---|---|---|
Level IV | 14 (18–87 years) | 3 L-PRP injections every 4 weeks | 12 m | Significant and linear improvement in KOOS. Pain reduced after movement and at rest | Modest pain persisting for days | [92] |
Level IV | 17 (30–70 years) | Single PRP injection | 12 m | Pain decreased, whereas function improved. MRI showed no worsening in 12 of 15 knees | Unreported | [93] |
Level IV | 27 (18–81 years) | 3 weekly L-PRP injections | 6 m | Substantial pain reduction after 1st injection and further improved at 6 months. WOMAC improved | No | [94] |
Level IV | 40 (33–84 years) | 3 weekly P-PRP injections | 6 m | Pain and disability subscores were significantly reduced | Transient sensation of hip heaviness | [95] |
Level IV | 50 (32–60 years) | 2 L-PRP injections every month | 12 m | IKDC and KOOS improved; all returned to previous activities | Unreported | [96] |
Level IV | 91 (24–82 years) | 3 injections of double-spun PRP activated by CaCl2 every 3 weeks | 12 m, 24 m | Pain decreased and knee function improved, especially in younger patients at 12 months. The improvements decreased at 24 months, but still better than the basal evaluation | Mild pain persisting for days | |
Level IV | 261 (mean 48 years) | 3 injections of CaCl2-activated P-PRP every 2 weeks | 6 m | Significant differences in VAS, SF-36, WOMAC and Lequesne index | No | [99] |
Level III | 30 (36–76 years) | 3 injections of double-spun PRP inactivated PRP or HA every 3 weeks | 6 m | Both improved in IKDC, WOMAC and Lequesne index, but PRP exhibited better scores | Pain, swelling, but resolved in days | [100] |
Level III | 60 (61 years in HA, 64 years in PRP) | 3 weekly injections of CaCl2-activated P-PRP or HA | 5 w | 33.4% patients in PRP group and 10% in HA achieved at least 40% pain reduction. Disability reduced more in PRP group than HA | Mild self-limiting pain and effusion in both groups | [101] |
Level II | 120 (19–77 years) | 3 weekly L-PRP or HA injections | 6 m | Better results in WOMAC and NRS in PRP than HA | Temporary mild worsening of pain | [102] |
Level II | 150 (26–81 years) | 3 injections double-spun PRP or HA every 2 weeks | 6 m | Higher IKDC but lower VAS pain scores than HA, especially in younger patients | No | [103] |
Level II | 32 (18–60 years) | 3 injections of CaCl2-activated P-PRP or HA every 2 weeks | 7 m | Higher AOFAS but lower VAS pain scores than HA | Mild pain, but self-resolved | [104] |
Level I | 78 (33–80 years) | Single or twice leukocyte-filtered PRP injection, or single saline injection | 6 m | WOMAC improved after PRP injection, whereas worsened after saline infiltration | Self-resolved nausea and dizziness | [105] |
Level I | 120 (31–90 years) | 4 weekly injections of inactivated P-PRP or HA | 6 m | Significantly better clinical outcome and lower WOMAC scores than HA | None observed | [106] |
Level I | 176 (41–74 years) | 3 weekly injections of CaCl2-activated P-PRP or HA | 6 m | 14.1% more patients reduced pain at least 50% in PRP group, with a significant difference | Mild, evenly in 2 groups | [107] |
Level I | 96 (50–84 years) | 3 injections of CaCl2-activated P-PRP every 2 weeks, or single HA injection | 48 w | Significantly more efficient in reducing pain, stiffness and improving physical function than HA | Mild, evenly in 2 groups | [108] |
Level I | 109 (18–80 years) | 3 weekly injections of double-spun PRP releasate after freezing and thawing or HA | 12 m | No significant difference in all scores. Only a trend favoring PRP in patients with early OA | Mild pain and effusion | [109] |